HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human

The purity of HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Z06622
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer[ Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGASGVGK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGASGVGK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human

    The purity of HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human

    HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.


Background
Target Background Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.